Plastic, Reconstructive, and Aesthetic Surgeon · PhD · National Secretary ISAPS Spain · Scientific Director of the Nixarian Institute
Reviewed: April 2026
Direct answer: PRP alone did not reduce inflammation compared to placebo in the randomized clinical trial by Goldstein et al. (JAAD, 2019). Fractionated CO₂ laser as monotherapy also showed no significant differences compared to placebo in the trial by Mitchell et al. (Obstetrics and Gynecology, 2021). The Liquenia-SVF protocol (nanofat + stromal vascular fraction by mechanical digestion), in contrast, demonstrated in biopsy significant reduction of fibrosis, decrease in CD3+ infiltrate, and increase in microvascular density at 12 months with a single session (Aesthetic Surgery Journal, 2025). The three treatments are distinct; they are not interchangeable.
Liquenia-SVF Protocol vs PRP vs CO₂ Laser — Evidence-Based Comparison
If you have vulvar lichen sclerosus and have been searching for treatment options, you have likely encountered at least these three names: PRP, laser, and stem cells. Sometimes presented as equivalents. Sometimes as if they were “the same but more modern.” They are not.
This article does what few pages do: put all three side by side with the actual data from published clinical trials—including those that showed negative results—explain why those results matter, and position the Liquenia-SVF protocol in that context with precision.
This is not a sales pitch. It is a rigorous scientific comparison written so you can make an informed decision.
Want to know which treatment is right for your case?
Request a personalized evaluation with Dr. Patricia Gutiérrez-Ontalvilla.
PRP (Platelet-Rich Plasma): What the Strongest Evidence Says
PRP is obtained from the patient’s own blood through centrifugation. It concentrates platelets—up to 94% compared to 6% in normal blood—which, when activated, release growth factors: PDGF, TGF-β, EGF, VEGF. These factors stimulate tissue repair, collagen formation, and microcirculation.
What PRP does not contain: stem cells. Platelets are cell fragments; they do not have the capacity to regulate autoimmunity or direct antifibrotic action.
The Study That Carries the Most Weight: Goldstein et al. (2019)
The most rigorous clinical trial available on PRP in vulvar lichen sclerosus is that of Goldstein et al., published in the Journal of the American Academy of Dermatology in 2019. Design: randomized, double-blind, placebo-controlled. 30 women with biopsy-confirmed diagnosis.
“PRP did not reduce histologic inflammation compared to the placebo group. Until well-designed studies show positive results, these negative results suggest that PRP alone does not adequately treat vulvar lichen sclerosus.”
— Goldstein et al., Journal of the American Academy of Dermatology, 2019
It is worth mentioning that a previous pilot study by the same group (2017) had shown decreased inflammation on biopsy in approximately 60% of patients. The 2019 randomized trial—with a higher level of evidence—did not confirm that finding.
What This Means in Practice
PRP may have a role as an adjuvant in initial or mild cases and as a complement to other treatments. There are case series with favorable results. However, level 1b evidence from the randomized controlled trial by Goldstein concludes that as monotherapy for moderate or severe vulvar lichen sclerosus, PRP has not demonstrated efficacy in reducing histologic inflammation. The 2025 ISAPS clinical practice guideline explicitly states this.
As we already explained in detail in our complete analysis of PRP in lichen sclerosus, the problem is not PRP itself, but its isolated use for a pathology that also requires immune modulation and antifibrotic action.
Fractionated CO₂ Laser: What Controlled Trials Actually Show
Fractionated CO₂ laser acts through thermal ablation microcolumns that stimulate collagen production and cellular renewal. It may improve symptoms and appearance in some patients. There are clinical series with favorable results. However, when subjected to the criterion of a controlled clinical trial without associated corticosteroids, the results change.
The Placebo-Controlled Trial That Changed the Guidelines: Mitchell et al. (2021)
The study by Mitchell et al., published in Obstetrics and Gynecology in 2021, is the most rigorous randomized clinical trial available on CO₂ laser as monotherapy in lichen sclerosus. Design: randomized, double-blind, placebo-controlled. 40 women with biopsy-confirmed diagnosis. Key condition: patients had to abstain from topical and systemic treatments for at least 4 weeks before inclusion.
The primary outcome was analysis of changes in biopsies before and after laser treatment.
“Fractionated CO₂ laser is not an effective treatment as monotherapy for vulvar lichen sclerosus.”
— Mitchell et al., Obstetrics and Gynecology, 2021
A second Swiss trial controlled with sham treatment (Krause et al., 2023, 63 women) reached the same conclusion: no differences between groups in symptoms or signs.
A systematic review of 7 randomized clinical trials (Wei et al., 2025, 332 patients) concluded that the evidence supporting the use of laser as monotherapy is limited, and the anti-inflammatory, antifibrotic, and scar-preventive benefits remain unproven. A previous pilot study by Dieter et al. (2023) in postmenopausal women also did not demonstrate significant histological changes attributable to laser.
What This Means in Practice
CO₂ laser may have a role as an adjuvant treatment: to reduce the thickness of refractory white plaques and facilitate corticosteroid penetration, always after ruling out malignancy. The 2025 ISAPS guideline is categorical: fractionated CO₂ laser should not be used as monotherapy in vulvar lichen sclerosus, given that placebo-controlled trials do not demonstrate significant clinical benefit.
Liquenia-SVF Protocol (Nanofat + SVF): Data from Published Trials
The Liquenia-SVF protocol combines nanofat—emulsified and microfiltered fat, rich in regenerative factors—with SVF—stem cell concentrate obtained by mechanical digestion of adipose tissue. Both are extracted from the patient herself in the same surgical procedure.
The evidence trajectory has two published milestones:
LIQUENIA Randomized Clinical Trial (2022): Nanofat + PRP vs Clobetasol
Design: randomized, prospective, single-center clinical trial. 19 patients with moderate-severe VLS confirmed by biopsy, non-responders to clobetasol. Groups: 9 patients received two infiltrations of nanofat + PRP three months apart; 10 patients continued with clobetasol propionate 0.05% according to standard protocol.
Results at 12 months in the nanofat + PRP group:
- Significant reduction in pain, itching, burning, and dyspareunia.
- Significant improvement in clinical signs: erosions, fissures, introital stenosis, pallor (white plaques).
- Biopsies: significant decrease in all types of inflammatory cells (lymphocytes, eosinophils, mast cells; all P 0.05).
- Quality of life: significant improvement.
- All VLS flares occurred only in the control group (clobetasol).
- No serious adverse events related to treatment.
Published in: Aesthetic Plastic Surgery, 2022. DOI: 10.1007/s00266-021-02718-1
Prospective Liquenia-SVF Study (2025): Nanofat + SVF — The Most Advanced Version
The evolution of the protocol incorporated the stromal vascular fraction (SVF) obtained by mechanical digestion, replacing PRP with an autologous stem cell concentrate. Design: prospective, open study. 18 women with refractory moderate-severe VLS. Single session.
Reduction in CSS symptom scale (from 20.12 to 4.71)
Reduction in 5D itch scale (from 6.82 to 2.35)
Follow-up duration — results maintained with 1 session only
Serious adverse events related to treatment
Histological results verified in biopsy at 12 months:
- Stromal hyalinization (fibrosis): significant reduction.
- CD3+ infiltrate (autoimmune inflammation): significant reduction.
- Microvascular density: significant increase.
Published in: Aesthetic Surgery Journal, Oxford University Press, 2025. DOI: 10.1093/asj/sjaf148
Important: the Liquenia-SVF protocol is indicated in moderate and severe cases that have not responded sufficiently to corticosteroids, and complements—does not replace—first-line conventional therapy. Vulvar lichen sclerosus remains a chronic condition (ISSVD, 2022) that requires long-term follow-up.
Comparative Table: PRP, CO₂ Laser, and Liquenia-SVF Protocol
| Parameter | PRP (platelet-rich plasma) | Fractionated CO₂ laser | Liquenia-SVF Protocol |
|---|---|---|---|
| Contains stem cells | No. Only platelet growth factors | Not applicable (physical energy) | Yes. ADSCs + SVF by mechanical digestion |
| Antifibrotic action in biopsy | Not demonstrated | Contradictory evidence. Negative as monotherapy | Yes. Significant reduction in stromal hyalinization |
| Action on immune infiltrate | Not demonstrated (Goldstein 2019) | Not demonstrated as monotherapy | Yes. Significant CD3+ reduction |
| Placebo-controlled trial | Yes — negative result (Goldstein 2019, JAAD) | Yes — negative result as monotherapy (Mitchell 2021) | Active comparator clobetasol. Superiority demonstrated (2022) |
| Sessions required | Several per year | 3-5 sessions. Does not replace corticosteroids | 1 session. Results maintained at 12 months |
| Position in ISAPS 2025 guidelines | Limited evidence. Only adjuvant | Do not use as monotherapy. Only adjuvant | Regenerative option for refractory VLS |
Sources: Goldstein et al. JAAD 2019 | Mitchell et al. Obstet Gynecol 2021 | Gutiérrez-Ontalvilla et al. Aesthetic Plastic Surgery 2022 | Gutiérrez-Ontalvilla et al. Aesthetic Surgery Journal 2025 | Gutiérrez-Ontalvilla et al. ISAPS Guideline 2025
Why They Are Not Interchangeable
The difference is in mechanism. PRP provides growth factors that stimulate repair but do not modulate the autoimmune response or reverse established fibrosis. Laser stimulates superficial cellular renewal and may facilitate corticosteroid absorption, but controlled trials demonstrate that alone, without corticosteroids, it does not produce significant histological changes.
The Liquenia-SVF protocol acts on the four mechanisms underlying lichen sclerosus damage simultaneously: immunoregulation, fibrosis inhibition, angiogenesis, and structural regeneration. This explains why changes are documented in biopsy and why they persist at 12 months with a single session.
The 2025 ISAPS guidelines, of which Dr. Gutiérrez-Ontalvilla is first author, explicitly establish that the regenerative protocol should complement conventional therapy, not replace it.
Have you tried corticosteroids without satisfactory response?
The Liquenia-SVF protocol is specifically designed for refractory moderate and severe cases. We evaluate your case individually.
What About Vulvar Lichen Planus?
Vulvar lichen planus shares the autoimmune basis of lichen sclerosus: T lymphocyte activation, chronic mucosal inflammation, progressive tissue destruction. Laser data as monotherapy are equally insufficient in this context. The Liquenia-SVF protocol is biologically relevant for lichen planus as well; candidacy evaluation is always performed individually in consultation.
“Before coming to Dr. Gutiérrez’s office, I had tried PRP elsewhere. They explained it was the same thing, but simpler. I did not improve. When I understood the difference between PRP and stem cells, and especially when I saw in the data what had occurred in the biopsies of other patients like me, for the first time I felt this could be different. And it was.”
— A.G., 45 years old, treated in 2024 at the Nixarian Institute, Valencia.
Download the scientific guide to the Liquenia-SVF protocol — data, biopsies, and frequently asked questions.
Frequently Asked Questions About Treatments for Vulvar Lichen Sclerosus
Can PRP be combined with the Liquenia-SVF protocol?
The first Liquenia clinical trial (2022) combined nanofat with PRP, without SVF, and obtained significant results. The current protocol replaces PRP with the stromal vascular fraction (SVF) obtained by mechanical digestion because the stem cell concentration is higher and histological results improve. Currently, PRP is not part of the standard Liquenia-SVF protocol.
Can laser be done together with the Liquenia-SVF protocol?
Laser could be used after the Liquenia-SVF protocol if necessary to reduce the thickness of refractory white plaques to facilitate subsequent corticosteroid penetration. Sequencing and indication are always decided individually in consultation.
Why does PRP have so many advocates if Goldstein’s data are negative?
Because there are limited case series and observational studies with positive results. However, the Goldstein trial (2019) is the highest level of evidence available (level 1b, randomized double-blind placebo-controlled). That is why guidelines establish that PRP cannot be recommended as first-line treatment as monotherapy.
Can laser worsen lichen sclerosus?
There is no evidence that laser worsens vulvar lichen sclerosus. Complications documented in studies are minor: transient discomfort and post-session sensitivity. As monotherapy, without concomitant corticosteroids, controlled trials do not demonstrate significant histological efficacy, but neither do they show harm to disease progression.
How many sessions of the Liquenia-SVF protocol are necessary?
In the 2025 study, results were obtained with a single session. At the Nixarian Institute, 10-year follow-up of patients from the first studies shows that only one patient (who had suffered from lichen sclerosus since childhood) has needed a booster session at 4 years. The vast majority maintain results with a single intervention.
Scientific References
- Gutiérrez-Ontalvilla P, Gomez Rojas A, Iborra Colomino M, et al. Clinical and Histopathological Investigation of Stromal Vascular Fraction and Nanofat in Vulvar Lichen Sclerosus. Aesthetic Surgery Journal. 2025. DOI: 10.1093/asj/sjaf148
- Gutiérrez-Ontalvilla P, Giner F, Vidal L, Iborra M. The Effect of Lipofilling and Platelet-Rich Plasma on Patients With Moderate-Severe Vulvar Lichen Sclerosus Who Were Non-Responders to Topical Clobetasol Propionate: A Randomized Pilot Study. Aesthetic Plastic Surgery. 2022. DOI: 10.1007/s00266-021-02718-1
- Gutiérrez-Ontalvilla P, Benito-Ruiz J, Cervantes A. State of the Art for Regenerative Management of Vulvar Lichen Sclerosus — ISAPS Clinical Practice Guideline. Aesthetic Plastic Surgery. 2025. DOI: 10.1007/s00266-025-05459-7
- Goldstein AT, Mitchell L, Govind V, Heller D. A Randomized Double-Blind Placebo-Controlled Trial of Autologous Platelet-Rich Plasma Intradermal Injections for the Treatment of Vulvar Lichen Sclerosus. Journal of the American Academy of Dermatology. 2019. DOI: 10.1016/j.jaad.2018.12.060
- Mitchell L, Goldstein AT, Heller D, et al. Fractionated Carbon Dioxide Laser for the Treatment of Vulvar Lichen Sclerosus: A Randomized Controlled Trial. Obstetrics and Gynecology. 2021. DOI: 10.1097/AOG.0000000000004409
- Krause E, Neumann S, Maier M, et al. LASER Treatment in Gynaecology — A Randomized Controlled Trial in Women with Symptomatic Lichen Sclerosus. European Journal of Obstetrics, Gynecology and Reproductive Biology. 2023. DOI: 10.1016/j.ejogrb.2023.06.003
- Wei D, Meng J, Li Q, et al. Efficacy and Safety of Laser Treatment in Vulvar Lichen Sclerosus: A Systematic Review. Lasers in Surgery and Medicine. 2025. DOI: 10.1002/lsm.70062
- Dieter AA, Iglesia CB, Lee JH, et al. A Prospective Pilot Study to Assess for Histologic Changes on Vulvar Biopsies in Postmenopausal Women With Lichen Sclerosus Treated With Fractionated CO₂ Laser Therapy. Lasers in Surgery and Medicine. 2023. DOI: 10.1002/lsm.23669
About the Author
Dr. Patricia Gutiérrez-Ontalvilla is a plastic, reconstructive, and aesthetic surgeon, Doctor of Medicine (PhD cum laude), and National Secretary of Spain at ISAPS. She directs the Nixarian Institute in Valencia, where she developed the Liquenia-SVF protocol for the treatment of vulvar lichen sclerosus. She is first author of the study published in Aesthetic Surgery Journal (2025) and of the ISAPS clinical practice guideline (2025) on regenerative management of lichen sclerosus. President of the Nixarian Foundation. Complete professional profile →
Take the Next Step with Information, Not Marketing
If you are seeking a treatment with verifiable scientific evidence for refractory vulvar lichen sclerosus, request a personalized evaluation of the Liquenia-SVF protocol.
